The 78% QoQ growth in new institutional accounts and 31% vial order growth signal early commercial traction, but without revenue dollars disclosed the magnitude of revenue conversion remains unclear. Watch the next 10-Q for actual revenue recognition, wholesale reorder frequency, and gross-to-net dynamics. The Q4 seasonal ramp and formulary target of 100 institutions by year-end are key catalysts.
Price Chart
Executive Summary
Citius Oncology reported positive commercial momentum for LYMPHIR in its Q3 2026 update, with new institutional accounts ordering the drug up 78% QoQ and total institutional vial orders rising 31% QoQ. The product is now available in 42 institutions with near-universal payer coverage, though no actual revenue figures were disclosed. This is the first detailed commercial update since the December 2025 U.S. launch.
Key Facts
- New institutional accounts ordering LYMPHIR increased 78% quarter over quarter
- Total institutional vial orders from wholesalers rose 31% during the quarter ended June 30, 2026
- LYMPHIR is now available in 42 institutions including academic oncology centers and NCCN institutions
- Near-universal payer coverage secured per company tracking
- Management estimates initial CTCL market for LYMPHIR currently exceeds $400 million
- Targeting formulary inclusion with 100 priority institutions by year-end
- Company anticipates more than 20 additional institutions during the current quarter
- LYMPHIR was FDA-approved and launched in the U.S. in December 2025
Financial Impact
No revenue figures disclosed. Operational metrics show 78% QoQ increase in new institutional accounts and 31% QoQ increase in vial orders from wholesalers. Management estimates the initial CTCL market exceeds $400 million. Revenue is recognized when wholesale orders are placed and filled.
Risk Factors
- No actual revenue figures disclosed — operational metrics may not translate to commensurate revenue due to gross-to-net deductions, patient starts lagging vial orders, and return provisions
- Commercial launch is only ~8 months old with a small dedicated sales team; sustainability of ordering growth is unproven
- Company faces Nasdaq continued listing standard compliance risk (noted in forward-looking statements)
- Near-universal payer coverage claim is company-tracked and not independently verified
- Reformulated denileukin diftitox carries a Boxed Warning for capillary leak syndrome, which may limit prescriber adoption
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-085434 |
| Document: ea0300371-8k_citius.htm | 0001213900-26-085434 |
| Document: 0001213900-26-085434-index-headers.html | 0001213900-26-085434 |
| Document: 0001213900-26-085434-index.html | 0001213900-26-085434 |
| Document: 0001213900-26-085434.txt | 0001213900-26-085434 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $0.6000 | awaiting T+5 | — | $0.5960 (−0.67%) |
Oct 26, 2026 today | Press Release | $0.6072 | awaiting T+5 | — | $0.5960 (−1.84%) |
Oct 23, 2026 3d ago | 8-K | $0.5795 | awaiting T+5 | — | $0.5960 (−2.85%) |
Aug 12, 2026 10w ago | 8-K | $0.8115 $0.7525 | ▼ −7.27% | ▼ −6.83% | $0.5960 (−26.56%) |
Aug 5, 2026 11w ago | 8-K | $0.7850 $0.8115 | ▲ +3.38% | ▲ +3.03% | $0.5960 (−24.08%) |
Jun 8, 2026 20w ago | EFFECT | $0.7999 $0.6802 | ▲ +14.96% | ▲ +17.08% | $0.5960 (+25.49%) |
Jun 1, 2026 21w ago | 8-K | $0.7830 $0.7200 | ▼ −8.05% | ▼ −5.08% | $0.5960 (−23.88%) |
May 29, 2026 21w ago | S-3 | $0.7920 $0.7800 | ▲ +1.52% | ▼ −1.24% | $0.5960 (+24.75%) |
May 15, 2026 23w ago | 8-K | $0.8290 $0.8600 | ▲ +3.74% | ▲ +2.12% | $0.5960 (−28.11%) |
Mar 3, 2026 34w ago | EFFECT | $1.06 $1.01 | ▼ −5.19% | ▼ −4.71% | $0.5960 (−43.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers